Biostax (BTAX) Akcja Kurs

Immune Therapeutics, Inc. engages in the development and marketing of pharmaceutical, biotechnology, and MedTech products. The company is headquartered in Winter Park, Florida. The company went IPO on 2001-07-16. Biostax has partnerships in the fields of autoimmunity and immune restoration, which focuses on delivering solutions for people living with autoimmunity, chronic inflammation, infection, and cancer. Its subsidiary BiostaxRx, is focused on the treatment of inflammaging disease. Its product portfolio includes Londonal, JKB-122 and Low Dose Naltrexone. Lodonal is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). JKB-122 is a therapy developed for the purposes of treating Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that shows anti-fibrotic, immune modulating, and/or anti-inflammatory effects.